Swedish Melanoma Detection Device To Be Piloted at Dallas-Area Bare Dermatology Clinics

Doctors can often identify signs of a melanoma through a visual examination of a patient’s skin, by using a dermoscope or other tools. But additional information is sometimes needed to make a precise diagnosis, according to SciBase, a medical tech company based in Stockholm, Sweden—which has developed a device it says provides exactly that.

The device, called Nevisense, uses small electrical impulses to detect cellular irregularities beneath the skin’s surface. SciBase says the method has been proven “in the world’s largest melanoma detection study of its kind,” and is “the only FDA-approved test for early melanoma detection at point-of-care.”

Today SciBase announced that it’s partnering with North Texas-based Bare Dermatology—which has five offices in the Dallas area—to pilot the device at select locations. Headquartered in Aubrey north of Dallas-Fort Worth, Bare Dermatology was founded in 2022.

Nevisense melanoma detection device [Photo: SciBase]

Dr. Aaron Farberg, chief medical officer of Bare Dermatology, said the device “can help us to identify melanoma at an early stage, which is critical for improving patient outcomes.”

“Melanoma is a leading cause of death among skin cancers, but when detected early, it has a nearly 100% cure rate,” Farberg added in a statement.

Pia Renaudin, who was recently appointed CEO of SciBase and is based in Sweden, said her company is focused on “addressing the need for early melanoma detection in the highest at-risk patient population in the U.S.”

“We’re expanding in the areas where melanoma rates are high,” Renaudin said of the Texas and Florida markets, where Nevisense is also being piloted. “We’re pleased to collaborate with Bare Dermatology as we expand across the U.S. to address the early detection of melanoma needs.”

Nevisense melanoma detection device [Photo: SciBase]

When diagnosing and treating melanoma, “timing is critical,” SciBase says on the company’s website. “If detected and treated early, a melanoma is largely curable. Nevisense gives your doctor immediate objective information, making it possible to quickly determine which steps are needed in your treatment.”

By providing objective diagnostic data, the company says, its device “helps doctors to make better and more accurate decisions about diagnosis and treatment in difficult cases. This ability to accurately measure your mole can reduce the need for unnecessary mole removals as well as the risk of leaving a potential melanoma undetected.”

Get on the list.
Dallas Innovates, every day.

R E A D N E X T

Evolon and ZeroEyes Partner on Long-Range AI Gun-Detection Technology
With the partnership, Dallas-based Evolon Technology will unite the long-distance object detection of its analytics with ZeroEyes' proprietary AI gun detection technology. The result: The ability to detect and track someone with a firearm more than a football field away. "Current events point to the need for a partnership like ours," Evolon President and CEO Kevin Stadler says.
Device From Coppell-Based Neurolens Measures 1 Millionth Patient Following $67M Raise
According to the NIH, up to 5% of people worldwide have improperly aligned eyesight—a condition known as strabismus. An even higher percentage of people suffer from computer vision syndrome—digital eye strain caused by prolonged use of digital devices. Today Neurolens announced a milestone in alleviating the conditions' symptoms, seven months after raising $67 million to fund the company's growth.
Dallas Invents: 152 Patents Granted for Week of May 23
Dallas-Fort Worth ranked No. 9 for patents out of 250 metros. Patents granted include: Bank of America's authentication using blockchains, Apple's beam tracking using downlink data reception and motion sensing information, USAA's color-changing vehicle to improve visibility, American Security Products' keyless courier entry for safes, Toyota's LiDAR reflective fabric, Akamai Technologies' detecting internet eavesdroppers, Anametric's preservation of qubits, Textron's takeoff power boost, Magic Leap's controlling virtual image generation system using emotional states of user, and Accenture's utilizing machine learning to prevent intellectual property issues for content during different stages of a project lifecycle.
Dallas Invents: 104 Patents Granted for Week of April 25
Dallas-Fort Worth ranked No. 10 for patents out of 250 metros. Patents granted include: AXIP Energy Services' carbon dioxide capture from exhaust gas, Bank of America's intelligent cash handling, Capital One's vehicle identification driven by AR, DFB Soria's topical treatment for skin malignancies using nanoparticles of taxanes, Noodle.ai's artificial intelligence platform, Pacesetter's communication session between an implantable medical device and an external device, RailPros' automated railroad signage device, Tango Networks' enabling call originations using SMS and hotline capabilities, and Textron's distributed battery bank for ducted-rotor aircraft..